Then conversely, SPOP inactivating mutations reduce the ubiquitinated degradation of PD-L1, significantly upregulate PD-L1 expression and reduce the number of tumor-infiltrating lymphocytes at tumor sites. This evidence concerns the gene CD274 and neoplasm.